CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Clovis Oncology Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Clovis Oncology Inc
5500 Flatiron Pkwy Unit 100
Phone: (303) 625-5000p:303 625-5000 BOULDER, CO  80301-2834  United States Ticker: CLVSCLVS

Business Summary
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201912/31/2018YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Ginger L.Graham 63 6/5/2019 6/13/2013
President, Chief Executive Officer, Co-Founder, Director Patrick J.Mahaffy 56 4/20/2009 4/20/2009
Co-Founder, Executive Vice President, Chief Regulatory Officer Gillian C.Ivers-Read 65 4/20/2009 4/20/2009
9 additional Officers and Directors records available in full report.

Business Names
Business Name
Clovis Oncology Denmark ApS
Clovis Oncology France SAS
Clovis Oncology Germany GmbH
9 additional Business Names available in full report.

General Information
Number of Employees: 468 (As of 12/31/2018)
Outstanding Shares: 54,815,202 (As of 11/1/2019)
Shareholders: 23
Stock Exchange: NASD
Federal Tax Id: 900475355
Fax Number: (302) 655-5049


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, December 12, 2019